Here’s a real breakdown of what it actually costs to maintain a lifted Duramax over the course of a year. From routine ...

Eli Lilly (LLY) closed the most recent trading day at $1,027.51, moving +1.8% from the previous trading session. This change outpaced the S&P 500's 1.07% loss on the day. At the same time, the Dow ...

Eli Lilly (LLY) shares spiked ~3% on Thursday after the obesity drugmaker posted Phase 3 data showing its next-gen therapy retatrutide can generate up to 24% of weight loss, a “best-in-class" efficacy ...

In the latest trading session, Eli Lilly (LLY) closed at $1,056.88, marking a +1.45% move from the previous day. This move outpaced the S&P 500's daily gain of 0.79%. Elsewhere, the Dow saw an upswing ...

Eli Lilly's recent long streak of correction for nine trading days calls for a look at the stock even as it has stabilised now. It's explained by stretched valuations and also the lowering of prices ...

The obesity and diabetes drug boom is no longer a one-cycle story. Demand for GLP-1 treatments continues to exceed supply, with physicians expanding use beyond diabetes into weight management and ...

Regulators at the U.S. Food and Drug Administration (FDA) are reportedly weighing whether to sharply accelerate early-stage review steps for Eli Lilly and Co.’s (NYSE: LLY) experimental oral ...

Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Long Term US Stocks to Buy Now. On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from ...

FDA chief's office said it wants to cut the filing review from 60 days to one week The office said it may cut those reviews to two or three weeks based on complexity The agency could decide on Lilly's ...

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products ...